Substance Name: ZMAPP
- A mixture of c13C6, c2G4, and c4G7 monoclonal antibodies for treatment of Ebola virus infection.
CDC: ZMapp, being developed by Mapp Biopharmaceutical Inc., is an experimental treatment, for use with individuals infected with Ebola virus. It has not yet been tested in humans for safety or effectiveness. The product is a combination of three different monoclonal antibodies that bind to the protein of the Ebola virus.
* denotes mobile formatted website
Links to Resources
Names and Synonyms
- Ebola treatment Zmapp
CAS Registry Number
System Generated Number